HerResolve
Pre-clinical- Indications
- Endometriosis
Company intelligence / Profile preview
Heranova Lifesciences has launched a microRNA-based liquid biopsy test for non-invasive detection of endometriosis. The company aims to commercialize this diagnostic while advancing two first-in-class non-hormonal/non-antibiotic therapies targeting endometriosis and bacterial vaginosis. Their R&D pipeline also includes genetic tests and microbiome assays supporting female fertility. Clinical validation data are not yet public but the diagnostics have received endorsement from key opinion leaders in the field.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Heranova Lifesciences.